
Background


- Hepatocellular carcinoma is rising in incidence globally and tripled in the US over the last 3 decades.
- Hepatocellular carcinoma is the 5th most common cancer and 2nd most common cause of cancer mortality worldwide
- Viral hepatitis is a significant risk for developing HCC
- Hepatitis viruses may have direct and indirect effects of hepatic carcinogenesis

Incidence of Liver Cancer



Source: GLOBOCAN 2012 (IARC)

Mortality of Liver Cancer



Source: GLOBOCAN 2012 (IARC)

Accessed from the WHO International Agency on Research on Cancer on 11/2/2017 Available from http://globocan.iarc.fr/Pages/Map.aspx

Liver Cancer in Maryland

- MD Mortality Trend : Rising 4.1%/ year since 2004*
- MD Comparable to US Incidence Rate 7.9 versus 7.8/100,000 (2010-2014)*
- MD Comparable to US Mortality Rate 6.5 versus 6.3/100,000 (2014)*
- Stage distribution and 5 Year Survival


43%, 31% local 27%, 11% regional 18%, 3% distant

Risk factors:

Chronic Hepatitis B and C, Cirrhosis, EtOH, Obesity, Diabetes Aflatoxin, Toxins, Anabolic steroids, Tobacco use, Parasites ***

Populations at risk:

45+ years, males
Asian Americans, Pacific Islanders, Hispanics



Speakers

- Eleanor Wilson MD, MHS. Asst professor of Medicine, Institute of Human Virology/Greenebaum Comprehensive Cancer, University of Maryland, Baltimore MD An overview of HCV/HCC Epidemiology in Maryland
- Stuart Ray MD, Professor of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD
 HCV Vaccine Approach to Prevent HCC
- Amy Kim MD, Asst Professor of Medicine, Johns Hopkins University, Baltimore MD Strategies to prevention and treatment of HCC.
- Shyam Kottilil MD, Ph.D. Professor of Medicine, Institute of Human Virology/Greenebaum Comprehensive Cancer, University of Maryland, Baltimore MD Approaches to Achieve an HBV functional Cure to prevent HCC